coteauBeta Get App

CVS

CVS Health Corporation
$93.45
-1.37% Oct 21 close
Health CareS&P 500 CompareTechnicals
-14%-1%+12%+25%+37%Oct 2025Oct 2026Apr 2026
CVSSPY
1W
+3.4%
1M
+6.7%
3M
-13.0%
6M
+24.1%
YTD
+20.5%
1Y
+16.1%

Live chart

Loading live chart…

What they do

CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units.

Healthcare · Healthcare Plans

For information only · Important disclosures

Grades vs sector

Momentum
42nd percentile in sector
C
12-1 return: +12.2%
Percentile within its GICS sector across the S&P 1500.
Growth
42nd percentile in sector
C
Revenue growth (YoY): +7.1%
Percentile within its GICS sector across the S&P 1500.
Value
80th percentile in sector
B+
Forward E/P: 9.2% · EBITDA/EV: 9.2%
Percentile within its GICS sector across the S&P 1500.
Profitability
32nd percentile in sector
D+
Profit margin: +1.2% · Return on equity: +6.2%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
ranked 144 of 499 · 12-month momentum 28.5%
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
Coteau Long Book
Not in the current book

News

More news
What Could Stop CVS Health Stock Over The Next Six Months?
Trefis · Oct 21
Alaska Airlines taps CVS Health exec for newly created tech role
CIO Dive · Oct 20
What Are Hims & Hers Health Stock Bears Missing?
Trefis · Oct 19
Alaska Airlines names Amaresh Siva Chief Information Technology Officer
PR Newswire · Oct 19
Management Raised The Bar For CVS Health Stock; Does The Chart Agree?
Trefis · Oct 19

Key stats

Market value$119.5B
P/E (last 12 months)24.6
P/E (next 12 months, estimated)10.9
52-week range$69.51 – $110.68
Revenue growth (latest quarter vs a year ago)+7.1%
Dividend yield2.81%
Analyst consensusStrong Buy (25)
Average analyst price target$115.48 (+24%)
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Looks undervalued
Model read-out from the numbers below, not advice. Score +3 (DCF counts double).
▲DCF (base case)above the price by 136%
▲Forward P/E vs sector10.9x vs median 17.6x
•Piotroski F-score6/9
•Altman Z2.5 (grey)
▼Net debt / EBITDA4.5x
▲Analyst target+24% (25 analysts)

Discounted cash flow

Bear
$109
+16%
growth 2% · disc. 8.2% · term. 2.0%
Base
$220
+136%
growth 7% · disc. 7.2% · term. 2.5%
Bull
$413
+342%
growth 10% · disc. 6.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Today's price implies shrinking cash flows: about -2% a year for 10 years.
Implied
-2%/yr
FCF, last 3 yrs
-17%/yr
FCF, last 5 yrs
-10%/yr
Revenue, last 3 yrs
+8%/yr
Revenue, last 5 yrs
+8%/yr
Same inputs as the DCF above: trailing free cash flow 11.8B, 7.2% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.60 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 29.9× · 35th pct
24.6×
cheaper
Forward P/E
sector median 17.6× · 19th pct
10.9×
cheaper
EV / EBITDA
sector median 15.8× · 35th pct
13.8×
cheaper
Price / sales
sector median 3.1× · 3rd pct
0.3×
cheaper
Price / book
sector median 3.5× · 15th pct
1.5×
cheaper
FCF yield
sector median 4.1% · 89th pct
9.8%
cheaper

Forward EPS $8.54 vs trailing $3.80 (+125% expected growth). Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
7.1%
Operating margin
2.0%
FCF margin
2.8%
Net margin
1.2%
Return on equity
6.1%
Return on invested capital
5.1%
Net debt / EBITDA
4.5×
Current ratio
0.9×
Interest cover
2.7×
Cash conversion (OCF/NI)
3.0×
Piotroski F-score 6/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 2.5 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$115
+24%
Analysts
25
Strong Buy
Range
$103–$145
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$402.1B$1.8B$7.8B
2024$372.8B$4.6B$6.3B
2023$357.8B$8.3B$10.4B
2022$322.5B$4.3B$13.4B
2021$292.1B$8.0B$15.7B
2020$268.7B$7.2B$13.4B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +7.6%.

Earnings

Next report: 2026-11-04 · before open · EPS est 1.65
24-1125-0225-0525-0725-1026-0226-0526-080.002.58
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-051.852.58+39.4%
2026-05-062.212.57+16.5%
2026-02-101.001.09+9.4%
2025-10-291.361.60+17.9%
2025-07-311.461.81+23.9%
2025-05-011.672.25+34.5%
2025-02-120.921.19+29.6%
2024-11-061.461.09-25.2%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$106.1B+7.3%
2026-03-31$100.4B–
2025-12-31$105.7B–
2025-09-30$102.9B–
2025-06-30$98.9B–
Rating changes
Reiterated
2026-10-12 · Leerink Partners reiterated Outperform on CVS
Reiterated
2026-09-03 · UBS reiterated Buy on CVS
Reiterated
2026-08-19 · Argus Research reiterated Buy on CVS
Reiterated
2026-08-12 · JP Morgan reiterated Overweight on CVS
Reiterated
2026-08-06 · UBS reiterated Buy on CVS
Reiterated
2026-08-06 · Evercore ISI Group reiterated Outperform on CVS

Third-party analyst actions, not Coteau's views. All rating changes

Recent dividends

2026-07-23: $0.665 · 2026-04-23: $0.665 · 2026-01-22: $0.665 · 2025-10-23: $0.665 · 2025-07-22: $0.665 · 2025-04-22: $0.665 · 2025-01-23: $0.665 · 2024-10-21: $0.665

Stats refreshed 2026-10-21 17:58:03 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

Beta 0.9 · Oct 21, 2026